<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294448</url>
  </required_header>
  <id_info>
    <org_study_id>PopPK profile of Qishe Pill</org_study_id>
    <nct_id>NCT02294448</nct_id>
  </id_info>
  <brief_title>PopPK Profile of Qishe Pill: Study Protocol for a Phase I Clinical Trial</brief_title>
  <official_title>Population Pharmacokinetic Modeling of Qishe Pill in Three Major TCM-defined Constitutional Types of Healthy Chinese Subjects: Study Protocol for a Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Qishe Pill (Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China), composed of
      processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae,
      Ovientvine, and Calculus Bovis Artifactus, has been developed and spread in use into clinical
      settings in 2009. As individualization has become the trend of modern medicine, a
      personalized medicine of Qishe Pill should be documented and practiced with various patients
      according to the ancient TCM system, a classification of personalized constitution type,
      which has been established to determine predisposition and prognosis to diseases as well as
      therapy and life-style administration. Therefore, we describe the population pharmacokinetic
      profile of Qishe Pill and compare its extent of metabolism in the 3 major Constitution Type
      (Qi-Deficiency, Yin-Deficiency and Blood-Stasis) to address major challenges of
      individualized and standardized Traditional Chinese Medicine into clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the greatly increased morbidity of neck pain, it brought a large challenge to some
      optimal therapies for various situations in population at a given time based on their
      demographic, physiological and pathological characteristics. Chinese proprietary herbal
      medicines, as a kind of Complementary and Alternative Medicine (CAM), are usually developed
      from some well-established and long-standing recipes and formulated as tablets or capsules
      for commerce, convenience or palatability. Although these advantage mentioned, a good
      quantification and a strict standardization in detail are still need to be improved for
      individualized implementation in therapeutic strategies. Based on the YQHY decoction (Yi-Qi
      Hua-Yu Decoction, tonify Qi and promoting circulation and removing stasis), Qishe Pill
      (Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) has been developed and spread
      in use into clinical settings in 2009. As individualization has become the trend of modern
      medicine, a personalized medicine of Qishe Pill should be documented and practiced with
      various patients according to the ancient TCM system, a classification of personalized
      constitution type, which has been established to determine predisposition and prognosis to
      diseases as well as therapy and life-style administration. Therefore, we describe the
      population pharmacokinetic profile of Qishe Pill and compare its extent of metabolism in the
      3 major Constitution Type (Qi-Deficiency, Yin-Deficiency and Blood-Stasis) to address major
      challenges of individualized and standardized Traditional Chinese Medicine into clinical
      practice.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>Dosing(0 hour)</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>15 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>30 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>45 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>60 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>90 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>120 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>150 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>180 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>240 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>360 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>480 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>600 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>720 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of Qishe Pill</measure>
    <time_frame>1440 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Qishe Pill</measure>
    <time_frame>2160 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma sampling of Qishe Pill for pharmacokinetic analysis</measure>
    <time_frame>2880 min after dosing</time_frame>
    <description>5 ml blood samples for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Dosing(0 hour)</time_frame>
    <description>body temperature, heart rate and blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>180 min after dosing</time_frame>
    <description>body temperature, heart rate and blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>720 min after dosing</time_frame>
    <description>body temperature, heart rate and blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>1440 min after dosing</time_frame>
    <description>body temperature, heart rate and blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>2160 min after dosing</time_frame>
    <description>body temperature, heart rate and blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>2880 min after dosing</time_frame>
    <description>body temperature, heart rate and blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG monitoring</measure>
    <time_frame>Dosing(0 hour)</time_frame>
    <description>Electrocardiograms (ECGs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG monitoring</measure>
    <time_frame>180 min after dosing</time_frame>
    <description>Electrocardiograms (ECGs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG monitoring</measure>
    <time_frame>720 min after dosing</time_frame>
    <description>Electrocardiograms (ECGs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG monitoring</measure>
    <time_frame>1440 min after dosing</time_frame>
    <description>Electrocardiograms (ECGs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG monitoring</measure>
    <time_frame>2160 min after dosing</time_frame>
    <description>Electrocardiograms (ECGs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG monitoring</measure>
    <time_frame>2880 min after dosing</time_frame>
    <description>Electrocardiograms (ECGs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Day 1 of drug administration and blood sampling</time_frame>
    <description>The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Day 2 of drug administration and blood sampling</time_frame>
    <description>The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Day 3 of drug administration and blood sampling</time_frame>
    <description>The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>Subjects will be requested to return to the study unit 4 d after drug administration and blood sampling for a follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Qishe Pill in low dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Qishe Pill in medial dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Qishe Pill in high dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in low dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The time to maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in medial dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The time to maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in high dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The time to maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in low dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in medial dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in high dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The distribution volume (DF) of Qishe Pill in low dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The distribution volume (DF) of Qishe Pill in medial dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The distribution volume (DF) of Qishe Pill in high dosage</measure>
    <time_frame>4 days after drug administration and blood sampling</time_frame>
    <description>The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deep phenotyping with genomics and functional genomics approaches</measure>
    <time_frame>Dosing(0 hour)</time_frame>
    <description>3 ml blood samples for genomic variants analysis. The cytochrome P450 gene family, such as CYP1A1, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4 and CYP3A5 , etc, will be chosen as the target objective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep phenotyping with genomics and functional genomics approaches</measure>
    <time_frame>2880 min after dosing</time_frame>
    <description>3 ml blood samples for genomic variants analysis. The cytochrome P450 gene family, such as CYP1A1, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4 and CYP3A5 , etc, will be chosen as the target objective.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Constitution in Chinese Medicine Questionnaire (CCMQ)</measure>
    <time_frame>During screening in the recuitment</time_frame>
    <description>Two qualified traditional Chinese medical doctors licensed by the Chinese government determine the constitution according to CCMQ</description>
  </other_outcome>
  <other_outcome>
    <measure>The Constitution in Chinese Medicine Questionnaire (CCMQ)</measure>
    <time_frame>2880 min after dosing</time_frame>
    <description>Two qualified traditional Chinese medical doctors licensed by the Chinese government determine the constitution according to CCMQ</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory measures and clinical assessment</measure>
    <time_frame>During screening in the recuitment</time_frame>
    <description>These parameters including blood count, electrolytes, renal and liver function parameters, blood lipids, age, gender, history of smoking, blood pressure, weight (kg), and height (meters) will be obtained for all subjects.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Individuality</condition>
  <condition>Narrative Medicine</condition>
  <arm_group>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China） in low dosage(3.75mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in medial dosage(7.5mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China）in high dosage(15mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishe Pill</intervention_name>
    <description>Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast</description>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_label>cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Aged 20-35

          -  18.5 kg/m2 ≤Body mass index (BMI) &lt;23 kg/m2

          -  TCM-constitutionally typed as either the 3 major type

        Exclusion

          -  History of impaired fasting glucose or diabetes mellitus (past history of diabetes or
             fasting blood glucose at screening ≥100 mg/dl)

          -  History of liver disease (hepatitis, hepatic cirrhosis) or hepatic dysfunction (AST or
             ALT at screening ≥40 U/L)

          -  History of renal dysfunction (creatinine at screening ≥1.2 mg/dl)

          -  History of heart disease (heart failure, angina pectoris, myocardial infarction,
             arrhythmia)

          -  History of malignant tumor

          -  Having digestive disorders that can interfere with normal absorption of standard diet
             (gastritis, gastric ulcer, duodenitis, duodenal ulcer, etc.)

          -  Smoking during the recent 3 months

          -  Alcohol consumption 3 or more times a week during the recent 3 months

          -  Women who were pregnant, intended to become pregnant, or breast- feeding

          -  Medicated during the recent month for therapeutic or prophylactic purposes

          -  Participating in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-jun Wang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xue-Jun Cui, Dr.</last_name>
    <email>13917715524@139.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yue-li Sun, Dr</last_name>
    <email>edisonlike2008@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Longhua Hospital, Shanghai University of TCM</name>
      <address>
        <city>Shanghai,</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue-li Sun, Dr</last_name>
      <email>edisonlike2008@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ting Hou, Miss</last_name>
      <email>Houting003@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yong-jun Wang, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Aker PD, Gross AR, Goldsmith CH, Peloso P. Conservative management of mechanical neck pain: systematic overview and meta-analysis. BMJ. 1996 Nov 23;313(7068):1291-6.</citation>
    <PMID>8942688</PMID>
  </reference>
  <reference>
    <citation>Cui X, Trinh K, Wang YJ. Chinese herbal medicine for chronic neck pain due to cervical degenerative disc disease. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006556. doi: 10.1002/14651858.CD006556.pub2. Review.</citation>
    <PMID>20091597</PMID>
  </reference>
  <reference>
    <citation>Wang Q. Classification of the nine basic TCM constitutional type and based expression and diagnosis. Journal of Beijing University of Traditional Chinese medicine. 2005.1-8</citation>
  </reference>
  <reference>
    <citation>Liu Mei, Zhang N, Wang YJ, Shi Q. Purification process research of major compound in Qishe Pill as Astragalus. Acta Chinese Medicine and Pharmacology. 2006(34):14-16.</citation>
  </reference>
  <reference>
    <citation>Zhang YQ, Liu XH, Zhang N, Liu M. Quality standard research of Qishe Pill. Lishizhen Med Mater Med Res. 2008(19): 977-979.</citation>
  </reference>
  <reference>
    <citation>Liu M, Zhang N, Wang YJ, Zhang YQ, Zhou CJ. Technology research of Qishe Pill, a new medicine for cervical spondylosis. Lishizhen Med Mater Med Res. 2010(21):176-179.</citation>
  </reference>
  <reference>
    <citation>Ge JR, Wang HM, Meng CX, Tong PJ. Effects of Qishe Pill, a compound traditional Chinese herbal medicine, on cervical radiculopathy: a randomized controlled trial for Phase III. Chinese Journal of New Drugs and Clinical. 2014(7):56-58.</citation>
  </reference>
  <reference>
    <citation>Johnson CL, Fulwood R, Abraham S, Bryner JD. Basic data on anthropometric measurements and angular measurements of the hip and knee joints for selected age groups 1-74 years of age. Vital Health Stat 11. 1981 Apr;(219):1-68.</citation>
    <PMID>15806754</PMID>
  </reference>
  <reference>
    <citation>Mäkelä M, Heliövaara M, Sievers K, Impivaara O, Knekt P, Aromaa A. Prevalence, determinants, and consequences of chronic neck pain in Finland. Am J Epidemiol. 1991 Dec 1;134(11):1356-67.</citation>
    <PMID>1755449</PMID>
  </reference>
  <reference>
    <citation>Bovim G, Schrader H, Sand T. Neck pain in the general population. Spine (Phila Pa 1976). 1994 Jun 15;19(12):1307-9.</citation>
    <PMID>8066508</PMID>
  </reference>
  <reference>
    <citation>van der Donk J, Schouten JS, Passchier J, van Romunde LK, Valkenburg HA. The associations of neck pain with radiological abnormalities of the cervical spine and personality traits in a general population. J Rheumatol. 1991 Dec;18(12):1884-9.</citation>
    <PMID>1795327</PMID>
  </reference>
  <reference>
    <citation>Hsu H-Y: 1986 Oriental MateriaMedica. Long Beach, CA: Oriental Healing Arts Institute; 1986.</citation>
  </reference>
  <reference>
    <citation>Zhu YB, Wang Q, Xue HS, Origasa H. Preliminary assessment on performance of constitution in Chinese medicine questionnaire. ZhongGuo Lin Chuang Kang Fu 2006; 10 (3): 15-17.</citation>
  </reference>
  <reference>
    <citation>FDA/CDER. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; 2005, http://www.fda.gov/downloads/drugs/guidance-complianceregulatoryinformation/guidances/ucm078932.pdf.</citation>
  </reference>
  <reference>
    <citation>EMEA. Strategies to identify and mitigate risks for first-in-human clinical trialswith investigational medicinal products; 2009, http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2009/09/WC500002988.pdf.</citation>
  </reference>
  <reference>
    <citation>Choo V. WHO reassesses appropriate body-mass index for Asian populations. Lancet. 2002 Jul 20;360(9328):235.</citation>
    <PMID>12133671</PMID>
  </reference>
  <reference>
    <citation>Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71.</citation>
    <PMID>7229908</PMID>
  </reference>
  <reference>
    <citation>Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51.</citation>
    <PMID>7334463</PMID>
  </reference>
  <reference>
    <citation>Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19.</citation>
    <PMID>6644555</PMID>
  </reference>
  <reference>
    <citation>Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008 Nov;66(5):629-39. doi: 10.1111/j.1365-2125.2008.03276.x. Epub 2008 Jul 31.</citation>
    <PMID>18771484</PMID>
  </reference>
  <reference>
    <citation>Zhang WJ, Hufnagl P, Binder BR, Wojta J. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-kappaB activation and adhesion molecule expression. Thromb Haemost. 2003 Nov;90(5):904-14.</citation>
    <PMID>14597987</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <last_update_submitted>November 15, 2014</last_update_submitted>
  <last_update_submitted_qc>November 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Cui xuejun</investigator_full_name>
    <investigator_title>Vice director</investigator_title>
  </responsible_party>
  <keyword>Cervical radiculopathy</keyword>
  <keyword>Neck pain</keyword>
  <keyword>Qishe pill</keyword>
  <keyword>raditional Chinese medicine</keyword>
  <keyword>healthy Chinese subject</keyword>
  <keyword>Population Pharmacokinetics</keyword>
  <keyword>Personalized Medicine</keyword>
  <keyword>Individualized Medicine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

